Navigation Links
Halo Pharmaceutical Welcomes Al Rosenston as its Vice President, Business Development
Date:1/26/2009

WHIPPANY, N.J., Jan. 26 /PRNewswire/ -- Adding to its strong executive team, Halo Pharmaceutical today announced the addition of Allen M. Rosenston, a thirty-five year pharmaceutical industry veteran, as Halo's new Vice President of Business Development. Al comes to Halo from a long and distinguished career at Abbott Laboratories where he held diverse roles in operations, business development, and related business functions. "The addition of Al to the Halo business development team is a significant achievement. Al has deep experience within the pharmaceutical industry. He developed Abbott's domestic Contract Pharmaceutical Manufacturing Business Unit and, at the time of his retirement, he was responsible for the global finished goods contract manufacturing business," according to Mohd Asif, Halo's Chief Financial Officer.

Al comes to Halo shortly after Halo's acquisition of its Whippany, NJ facility, a facility which has been producing various dosage forms for 35 years. "I am thrilled to be part of the Halo Pharmaceutical team, and to build on the legacy of this outstanding facility and group of talented people with an average seniority of over 20 years. Based on my discussions with the new Halo team, this is a unique opportunity to create a world-class pharmaceutical services company right in the heart of New Jersey. Maintaining focus on quality, service, and compliance, along with the flexible manufacturing capabilities of the Whippany facility, will create a high-level of interest with prospective customers. I anticipate us to be highly competitive when overall service value is assessed."

Halo capabilities include an impressive array of formulation services, operations for the aseptic filling of topical ointments, solid dosage forms (tablets and capsules), liquids, suppositories, associated packaging (tablet, powder, liquids and HUD) and ample laboratory space for formulation development, pre-clinical and clinical supplies and support of commercial operations. An additional asset is the site's capability to manufacture controlled substances (C2-C5) and an API manufacturing unit with an outstanding track-record of meeting DEA requirements.

Al joined Halo on January 5, 2009, and can be reached at arosenston@halopharma.com or at 973-428-4087.

About Halo Pharmaceutical

Halo Pharmaceutical, headquartered in Whippany, NJ, is a full-service, specialty pharmaceutical company, offering state-of-the-art contract manufacturing, early stage formulation development and laboratory services to the pharmaceutical and related industries. Halo is currently a supplier of choice to a number of large and medium size brand pharmaceutical companies for important lifecycle products. Contract manufacturing capabilities include the ability to conduct aseptic filling, granulation, blending, tableting, coating, packaging, and related warehousing operations. Halo Pharmaceutical is a privately-held company.


'/>"/>
SOURCE Halo Pharmaceutical
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. KV Pharmaceutical Suspends Product Manufacturing, Shipping
2. KV Pharmaceuticals Launch of Gestiva(TM) Delayed
3. Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals
4. Caraco Pharmaceutical Laboratories, Ltd. to Announce Third Quarter of Fiscal Year 2009 Results on January 29, 2009
5. University Medical Pharmaceuticals Appoints Tom Roche as Senior Vice President, Global Sales and Marketing
6. Amylin Pharmaceuticals to Webcast Year-End Results
7. Renhuang Pharmaceuticals, Inc. Engages New Independent Auditor
8. Abbott Opens New Pharmaceutical Research Laboratory in Singapore
9. Law Firm Freedland Russo Spearheads Record-Setting Whistleblower Case Against Pharmaceutical Giant Eli Lilly -- Firm Expands Offices to Include L.A. Entertainment Branch
10. NUCRYST Pharmaceuticals appoints a new director
11. Peptimmune Grants Major Pharmaceutical Company Exclusive Option to License PI-2301 for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest ... its plans to open a flagship location in Covington, LA at 401 N. U.S. ... Go store next to Office Depot in the Holiday Square shopping center. Its location ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally ... care, have expanded their existing home health joint venture through an agreement, effective ... operating a joint venture home health company with Asante, delivering clinically integrated care, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the ... a year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, ... retirement havens have extremely low property-tax rates, which contributes to the relatively lower ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will host its ... on Friday, November 3, 2017, beginning at 7:00 a.m. ... 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... and guidance for 2018, Hill-Rom executives will also highlight ... and long-range financial outlook through 2020. ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: